Drugs / Measles, mumps, and rubella live attenuated virus
Measles, mumps, and rubella live attenuated virus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01188343 | Aug 2010 → Jul 2012 | Japanese encephalitis, measles, mumps infectious disease, rubella | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella live attenuated virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01188343 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella live attenuated virus vaccine (MMR)” NCT01188343 ↗ |
| Route | Subcutaneous | “0.5 mL each; Subcutaneous (SC)” NCT01188343 ↗ |